PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.48%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
3.86%
Positive operating income growth while TRAW is negative. John Neff might view this as a competitive edge in operations.
-1.47%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
12.77%
Positive EPS growth while TRAW is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
13.49%
Diluted EPS growth under 50% of TRAW's 100.00%. Michael Burry would worry about an eroding competitive position or excessive dilution.
16.41%
Share count expansion well above TRAW's 2.96%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
17.29%
Slight or no buyback while TRAW is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
23.86%
Positive OCF growth while TRAW is negative. John Neff would see this as a clear operational advantage vs. the competitor.
23.57%
Positive FCF growth while TRAW is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21198.65%
Negative 10Y OCF/share CAGR while TRAW stands at 95.66%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-19211.55%
Negative 5Y OCF/share CAGR while TRAW is at 95.66%. Joel Greenblatt would question the firm’s operational model or cost structure.
-43.46%
Negative 3Y OCF/share CAGR while TRAW stands at 90.26%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-15978.83%
Negative 10Y net income/share CAGR while TRAW is at 85.36%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-50766.69%
Negative 5Y net income/share CAGR while TRAW is 85.36%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
48.21%
3Y net income/share CAGR 50-75% of TRAW's 85.74%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
19776.75%
10Y equity/share CAGR above 1.5x TRAW's 100.75%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
4394.26%
5Y equity/share CAGR above 1.5x TRAW's 100.75%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
625.15%
Positive short-term equity growth while TRAW is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.51%
Positive asset growth while TRAW is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
8.68%
Positive BV/share change while TRAW is negative. John Neff sees a clear edge over a competitor losing equity.
No Data
No Data available this quarter, please select a different quarter.
-31.37%
Our R&D shrinks while TRAW invests at 17.61%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
108.24%
We expand SG&A while TRAW cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.